The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin2015658710825651787
   PubMed Web of Science ®Google Scholar
• Villarreal-GarzaCde la MataDZavalaDGMacedo-PerezEOArrietaOAggressive treatment of primary tumor in patients with non-small-cell lung cancer and exclusively brain metastasesClin Lung Cancer20131461322682668
   PubMedGoogle Scholar
• SocinskiMAEvansTGettingerSTreatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest2013143e341Se368S23649446
   PubMed Web of Science ®Google Scholar
• ShepherdFAPereiraJCiuleanuTNational Cancer Institute of Canada Clinical Trials GroupErlotinib in previously treated non-small-cell lung cancerN Engl J Med200535312313216014882
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936194795719692680
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKNorth-East Japan Study GroupGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med20103622380238820573926
   PubMed Web of Science ®Google Scholar
• CappuzzoFCiuleanuTStelmakhLSATURN InvestigatorsErlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyLancet Oncol20101152152920493771
   PubMed Web of Science ®Google Scholar
• HanJYParkKKimSWFirst-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol2012301122112822370314
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRSpanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia ToracicaErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol20121323924622285168
   PubMed Web of Science ®Google Scholar
• RosellRMoranTQueraltCSpanish Lung Cancer GroupScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med200936195896719692684
   PubMed Web of Science ®Google Scholar
• Paz-AresLSoulièresDMelezinekIClinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysisJ Cell Mol Med201014516920015198
   PubMed Web of Science ®Google Scholar
• MitsudomiTMortiaSYatabeYWest Japan Oncology GroupGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol20101112112820022809
   PubMed Web of Science ®Google Scholar
• PallisAGFennellDASzutowiczELeighlNBGreillierLDziadziuszkoRBiomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancerBr J Cancer20111051821654681
   PubMed Web of Science ®Google Scholar
• PetrelliFBorgonovoKCabidduMBarniSEfficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell-lung cancer: a meta-analysis of 13 randomized trialsClin Lung Cancer20121310711422056888
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer20094522824719097774
   PubMed Web of Science ®Google Scholar
• TrottiAColevasADSetserACTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSemin Radiat Oncol20031317618112903007
   PubMed Web of Science ®Google Scholar
• PortaRSánchez-TorresJMPaz-AresLBrain metastases from lung cancer responding to erlotinib: the importance of EGFR mutationEur Respir J20113762463120595147
   PubMed Web of Science ®Google Scholar
• ParkSJKimHTLeeDHEfficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 2l mutationLung cancer20127755656022677429
   PubMed Web of Science ®Google Scholar
• IuchiTShingyojiMSakaidaTPhase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinomaLung Cancer20138228228724021541
   PubMed Web of Science ®Google Scholar
• FanYXuXXieCEGFR-YKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published dataOnco Targets Ther20141020752084
   Google Scholar
• EichlerAFKahleKTWangDLEGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancerNeuro Oncol2010121193119920627894
   PubMed Web of Science ®Google Scholar
• WelshJWKomakiRAminiAPhase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancerJ Clin Oncol20133189590223341526
   PubMed Web of Science ®Google Scholar
• WuYLZhouCChengYErlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)Ann Oncol20132499399923129122
   PubMed Web of Science ®Google Scholar
• FauquetteWAmouretteCDehouckMPDiserboMRadiation-induced blood-brain barrier damages: an in vitro studyBrain Res2012143311412622153623
   PubMed Web of Science ®Google Scholar
• TaniguchiKOkamiJKodamaKHigashiyamaMKatoKIntratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinibCancer Sci20089992993518325048
   PubMed Web of Science ®Google Scholar
• ParkSHolmes-TischAJChoEYDiscordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancerJ Thorac Oncol2009480981519487967
   PubMed Web of Science ®Google Scholar
• GowCHChangYLHsuYCComparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancerAnn Oncol20092069670219088172
   PubMed Web of Science ®Google Scholar
• Gomez-RocaCRaynaudCMPenault-LlorcaFDifferential expression of biomarkers in primary non-small cell lung cancer and metastatic sitesJ Thorac Oncol200941212122019687761
   PubMed Web of Science ®Google Scholar
• DanieleLCassoniPBacilloEEpidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancerJ Thorac Oncol2009468468819404216
   PubMed Web of Science ®Google Scholar
• SunMBehrensCFengLHER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumorsClin Cancer Res2009154829483719622585
   PubMed Web of Science ®Google Scholar
• BaykaraMKurtGBuyukberberSManagement of brain metastases from non-small cell lung cancerJ Cancer Res Ther20141091592125579528
   PubMedGoogle Scholar
• PruittAAMedical management of patients with brain tumorsCurr Treat Options Neurol20111341342621557041
   PubMedGoogle Scholar
• TasoMNRadesDWirthARadiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guidelinePract Radiat Oncol2012221022525925626
   PubMedGoogle Scholar
• KimSTUhmJELeeJRandomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapyLung Cancer201275828821684626
   PubMed Web of Science ®Google Scholar
• KimJELeeDHChoiYEpidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasisLung Cancer20096535135419157632
   PubMedGoogle Scholar
• HeonSYeapBYBrittGJDevelopment of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinibClin Cancer Res2010165873588221030498
   PubMed Web of Science ®Google Scholar